The MILs™ platform has the power and flexibility to improve cell therapies across the medical landscape, creating better, more durable clinical responses in patients.
WindMIL intends to investigate the vast possibilities that may benefit from the differentiating features of MILs to create a broad pipeline of next-generation cell therapies based on our unique and proprietary process of activating and expanding memory T cells from the bone marrow.
We are proud to have forged partnerships with Bristol Myers Squibb for the clinical study of non-small cell lung cancer (NSCLC), and with the University of Pennsylvania for exploring MILs as the basis for next-generation CAR-T therapy (CAR-MILs™).
In Cell Therapy, Cell Source Matters™
WindMIL is exploring collaborations and partnerships that leverage our unique know-how and proprietary position in bone-marrow derived immunotherapies, including opportunities with non gene-modified MILs and genetically-modified MILs.
Potential partners and collaborators are invited to contact WindMIL at email@example.com.